Various studies have investigated the role of central opioid peptides in feeding behavior; however, only a few have addressed the participation of opioids in the control of salt appetite. The present study investigated the effect of intracerebroventricular injections of the ␦-opioid antagonist, naltrindole (5, 10 and 20 nmol/rat) and the agonist, deltorphin II (2.5, 5, 10 and 20 nmol/rat) on salt intake. Two protocols for inducing salt intake were used: sodium-depletion and the central injection of angiotensin II. In addition, the effect of a central ␦-opioid receptor blockade on locomotor activity, on palatable solution intake (0.1% saccharin) and on blood pressure was also studied. The blockade of central ␦-opioid receptors inhibits salt intake in sodium-depleted rats, while the pharmacological stimulation of these receptors increases salt intake in sodium-replete animals. Furthermore, the blockade of central ␦-opioid receptors inhibits salt intake induced by central angiotensinergic stimulation. These data suggest that during sodium-depletion activation of the ␦-opioid receptors regulates salt appetite to correct the sodium imbalance and it is possible that an interaction between opioidergic and angiotensinergic brain system participates in this control. Under normonatremic conditions, ␦-opioid receptors may be necessary to modulate sodium intake, a response that could be mediated by angiotensin II. The decrease in salt intake following central ␦-opioid receptors blockade does not appear to be due to a general inhibition of locomotor activity, changes in palatability or in blood pressure.
Introduction
The endogenous opioid system is widely distributed throughout the brain and has been shown to be involved in multiple functions including antinociception, mood, feeding and drinking behavior, cardiovascular control and endocrine regulation [8] . Opioid peptides are classified into four well-defined pharmacological families: endorphins, enkephalins, dynorphins and nociceptin/orphanin FQ that act through G-protein-coupled receptors referred to as mu, delta, kappa and nociceptin/orphanin FQ receptor [8, 68, 69] . Of these opioid receptors, ␦-opioid receptors are particularly interesting as an alternative to -opioid drugs for the clinical treatment of chronic pain [5, 10, 73] . In the near future, drugs targeted at ␦-opioid receptors may also be used as therapeutic tools in addictive and impulsive disorders, as well as in anxiety and depression [58] .
Different studies have demonstrated the participation of the brain opioid system in the regulation of feeding behavior through a mechanism that may involve modulation of the reward-related responses and the palatability of different substances [9, 42, 44, 66] . Indeed, morphine and opioid agonists induce a preference for fat and sweet food/solutions [9, 26] . Few studies have addressed the role of opioid peptides in salt intake. The antagonist opioid, naloxone, administered both systemically and into the central nervous system, reduces the intake of hypertonic, hypotonic and isotonic saline solutions, which are preferred over water by fluid-deprived rats [15, 25, 27, 28] . On the contrary, intracerebroventricular injections of selective ␦-, -and -opioid agonists increase saline intake in non-deprived rats [27, 28] . Previous data from our laboratory have shown that -opioid receptors may regulate salt appetite, since intracerebroventricular injections of nor-binaltorphimine (Nor-BNI), a -opioid receptor antagonist, inhibit salt intake in sodium-depleted rats [55] . In addition, ␦-opioid receptors also appear to be involved in the control of ingestive behavior related to palatable substances. Deltorphin II, a ␦-opioid receptor agonist, injected intracebroventricularly, has been shown to increase sucrose solution intake [60] , while the antagonist, naltrindole, had no effect on sucrose solution intake [3] . In a study using the two-bottle choice test approach (water and saline solution 0.6% and 1.7%) in fluid-deprived rats, central administration of -and -antagonists, but not ␦-antagonists, decreases water intake. In addition, all the antagonists used in that study were able to alter saline solution intake [7] . On the other hand, salt intake in sodium-depleted rats is decreased by subcutaneous injection of naltrindole, a ␦-opioid antagonist [45] . However, in that study, a single dose of naltrindole was used and this was the only approach used to study salt appetite. In order to clarify the role of ␦-opioid receptors in the control of salt appetite, the present study was designed to investigate the effect of intracerebroventricular injections of different doses of a ␦-opioid agonist and antagonist using two different approaches. These approaches have been largely used in the literature to study salt intake: (1) sodium deficiency produced by a single administration of the diuretic furosemide; and (2) intracerebroventricular injection of angiotensin II in rats with normal sodium balance. In addition, the effect of central ␦-opioid receptor blockade on locomotor activity, on palatable solution intake (0.1% saccharin) and on blood pressure was also investigated. The hypothesis is that central ␦-opioid receptors participate in modulating salt intake during homeostatic challenges and may be important for the correction of sodium imbalance.
Methods

Animals
The present study used adult male Wistar rats weighing 250-280 g. The animals were kept under controlled light (lights on from 5 AM to 7 PM) and temperature (22 ± 2 • C) conditions with free access to tap water and laboratory chow (Nuvital Nutrientes Ltda., Curitiba, Brazil). Groups of rats used in one experimental set were not reused in any other part of the study. All experiments were conducted between 7 AM and 11 AM. The experimental protocols were performed in accordance with the regulations for the care of laboratory animals and were approved by the Institution's Animal Ethics Committee (CEUA-ICS-UFBA # 024/2012).
Surgical procedures
The animals were anesthetized with ketamine/xylazine (80/7 mg/kg i.p.) to allow the guide cannula (22-gauge) to be inserted into the lateral ventricle (LV) in accordance with the following coordinates: anteroposterior = 0.9 mm behind the bregma; lateral = 1.5 mm; vertical = 4.0 mm below the skull. The guide cannula was fixed to the skull with metal screws and dental cement and an obturator was provided to avoid obstruction. After surgery, the animals were housed in individual cages and had free access to laboratory chow, distilled water and 1.5% saline solution. The animals were handled every day to minimize the stress of the experimental procedure. The position of the guide cannula in the LV and the intracerebroventricular injection site were confirmed at the end of the experiment with the use of Evans Blue dye injected through the cannula. The brains were removed, placed in formalin, and later frozen and cut into 40 m sections. The slices were stained with cresyl violet and analyzed using light microscopy. Only data from the animals in which the tip of the cannula was restricted to the cerebroventricular space and the Evans Blue dye could not be seen in the brain tissue surrounding the ventricle were included in the study.
Drugs and microinjections
The drugs used were naltrindole (NTI), an opioid antagonist selective to ␦-opioid receptors [57] ; deltorphin II (Delt-II), an opioid agonist with high selectivity and affinity to ␦-opioid receptors [20, 38] ; and angiotensin II (AII). Both NTI and Delt-II were acquired from Tocris Bioscience, Ellisville, MO, USA, while AII was purchased from Sigma Chemical, Co., St. Louis, MO, USA. The doses of the drugs used in this study were compatible with previous reports: 5, 10 and 20 nmol/rat of naltrindole [7] , while the doses of deltorphin II were 2.5, 5, 10 and 20 nmol/rat [72] and 10 ng/rat of AII [21] . Central injections were given using a Hamilton microsyringe connected to a 30-gauge injector through polyethylene tubing (PE10). A total volume of 2 l was slowly injected (60 s). Furosemide, a loop diuretic, was purchased from Sanofi-Aventis Ltd., São Paulo, Brazil.
Sodium depletion (Experiments 1, 2 and 3)
Sodium depletion was achieved by means of a subcutaneous injection of furosemide (20 mg/kg). After the injections, the rats had free access to distilled water, while the standard rat chow was replaced by a low sodium diet (0.001% Na + and 0.33% K + ). In Experiment 1, the participation of central ␦-opioid receptors in the regulation of salt appetite was tested in different groups of sodiumdepleted animals receiving LV injections of NTI at different doses (5, 10 and 20 nmol) or saline. In Experiment 2, sodium-depleted animals received an LV injection of 20 nmol of NTI plus Delt-II at the doses of 2.5, 5, 10 and 20 nmol, or saline, to confirm the specificity of NTI. In both experimental sets, sodium-depleted control animals received LV injections of isotonic saline solution. In Experiment 3, the aim was to test the effect of pharmacological stimulation of the central ␦-opioid receptors on salt appetite. Sodium depleted rats and normonatremic animals (not submitted to sodium-depletion) received an LV injection of 20 nmol of Delt-II or saline. In all three experimental sets, bottles containing hypertonic saline solution (1.5%) and distilled water were reintroduced into the cages 15 min after the central injections. Fluid intake measurement began 5 min later and continued for the next 120 min. To confirm the efficacy of sodium depletion, an additional control group was included. In this group, the animals received subcutaneous injections of isotonic saline solution instead of furosemide and LV injections of isotonic saline solution. As expected, salt intake was significantly higher in the sodium depleted (furosemide treated) rats compared to the normonatremic (saline treated) rats, as shown in Table 1 .
Central angiotensinergic stimulation (Experiment 4)
In this experimental group, the objective was to study the role of ␦-opioid receptors in the salt appetite induced by the pharmacological stimulation of central angiotensinergic pathways. Different groups of normonatremic rats received LV injections of NTI at different doses (5, 10 and 20 nmol) 15 min before receiving AII (10 ng/rat). Bottles containing 1.5% saline solution and distilled water were replenished and made available immediately after the LV injections of AII. As in the previous experimental sets, the measurement of fluid intake began 5 min after reintroduction of the bottles into the cages and continued for the next 120 min.
Open field test (Experiment 5A)
The aim of this experimental set was to exclude the possibility that the ␦-opioid receptor antagonist could have induced a locomotor alteration that would explain the inhibition of salt intake observed in experiments 1 and 3. Different groups of sodium-depleted rats receiving LV injections of NTI (20 nmol) or saline solution were submitted to an open field test. In this test, the Table 1 Effect of sodium depletion induced by furosemide treatment and low sodium diet on salt and water intake.
Fluid intake
Water intake (ml/100 g b.w.) Salt intake (ml/100 g b.w.) Treatment NN (n = 12) SD (n = 11) NN (n = 12) SD (n = 11) Data presents as mean ± SEM. The data were analyzed by a mixed-model analysis of variance (ANOVA) with one repeated measures factor (eight levels of time) and one group factor (treatment:NN × SD) not repeated. SD = sodium depleted; NN = normonatremic. * Significant difference when the fluid intake by SD rats is compared to NN rats (Bonferroni's post-test).
animals were placed in a circular acrylic box (60 cm in diameter and 60 cm high) with an open top 30 min after an injection of NTI or saline solution into the LV. The floor was divided into eight areas of equal size with a circle at the center (42.43 cm). Hand-operated counters and stopwatches were used to score locomotion over a 10-min period by measuring the number of areas into which the rats entered with all four paws. The behavioral experiments took place in a sound-attenuated, temperature-controlled (24 ± 1 • C) room between 7 AM and 11 AM. A white-noise generator provided constant background noise and the apparatus was cleaned with 70% ethanol and dried before each session to minimize olfactory cues.
Dessert test (Experiment 5B)
The dessert test, a well-established model of hedonic behavior in rats, was performed to exclude the possibility of a non-specific, general inhibition of the central nervous system induced by the ␦-opioid receptor antagonist observed in experiments 1 and 3 [19, 33] . In this experiment, after LV cannulation, the animals were kept in the usual individual cages during the training period with free access only to tap water and were transferred to a different cage (the "test cage") for 2 h each day for seven consecutive days. In the test cage, the animals had access to two bottles: one containing water and the other containing a 0.1% saccharin solution. After this training period, the animals were divided into two groups and deprived of fluid for 24 h. Afterwards, the animals received LV injections of NTI (20 nmol) or saline (controls) 15 min before being transferred to the test cage. Intake of the water and the 0.1% saccharin solution was recorded over a 120-min period.
Blood pressure recording (Experiment 6)
In this experimental group, the objective was to exclude the possibility that the inhibitory effect of the ␦-opioid receptor antagonist on salt appetite could be due to changes in blood pressure. One day before the experimental sessions, a catheter (PE50) filled with heparin solution (1000 U/ml) was inserted into the left carotid artery under ketamine/xylazine (80/7 mg/kg i.p.) anesthesia, and exteriorized at the nape of the animal's neck to permit blood pressure recording. At the experimental session, the carotid catheter was connected to a pressure transducer whose signal was amplified and digitally recorded by an analog-to-digital interface (AqDados, version 5, Lynx Tecnologia Eletrônica Ltda, São Paulo, Brazil) and recorded (1 kHz) on a microcomputer for posterior analysis. Distinct groups of sodium-depleted animals received an LV injection of NTI (20 nmol) or saline solution (controls) 20 min after baseline blood pressure was recorded. In each of these groups, blood pressure continued to be recorded for the next 120 min after NTI or saline solution was injected. The experimental protocol used in this case was identical to that used to study salt intake in the previous groups. Mean arterial pressure (MAP) was calculated from systolic and diastolic pressure measurements using the AcqKnowledge software program, version 3.5.7, developed by Biopac Systems, Inc., California, USA. The MAP values at the end of the stabilization period were used as references to calculate the delta values that are presented here.
Statistical analysis
The data are presented as means ± standard error of the mean (SEM). Statistical analyses were performed using the GraphPad Prism software (GPAD, version 6.03, San Diego, USA). The amount of water and sodium chloride solution consumed was analyzed separately using a mixed-model analysis of variance (ANOVA) with time as the within-subjects repeated measure (eight levels of time) and drug treatment as the between-subjects variables (not repeated). The Bonferroni post hoc test was used to compare the effects of the drugs during each measurement period. The data from the open field and dessert tests were analyzed using Student's t-test. The delta values of MAP were analyzed using two-way repeated-measures ANOVA followed by the Bonferroni post hoc test. Differences between the groups were considered statistically significant when p < 0.05.
Results
Experiment 1 -effect of central ı-opioid receptor blockade on salt appetite in sodium-depleted rats
Cumulative salt intake in sodium-depleted rats after LV injections of NTI at the doses of 5 (n = 10), 10 (n = 10) and 20 nmol (n = 10) is shown in Fig. 1 (Panel A) . As expected, salt intake was The amount of water and sodium chloride solution consumed was analyzed separetely using a mixed-model analysis of variance (ANOVA) with one repeated measures factor (eight levels of time) and one group factor (drugs) not repeated. The post hoc test used to compare the effect of the drugs at each measurement time period was Bonferroni and is shown in Fig. 1-3 . SD = sodium depleted; NN = normonatremic.
high in the sodium-depleted rats receiving LV injections of isotonic saline (n = 11). The LV injection of NTI induced a dose-dependent inhibition of salt intake in sodium-depleted rats. NTI injections at the doses of 10 and 20 nmol promoted an inhibitory effect that began after the initial 15 min of the measurement period and lasted until the end of the experiment. At the lowest dose (5 nmol), the inhibitory effect was significant only at 120 min of the measurement period. Furthermore, in the sodium-depleted rats receiving LV injections of 5 nmol of NTI, salt intake was significantly different from that of the animals treated with NTI at the doses of 10 and 20 nmol after the first 30 min of the measurement period. Fig. 1 (Panel B) shows the effect of LV injections of NTI at the doses of 5, 10 and 20 nmol on water intake in sodium-depleted rats. As expected, water intake was negligible in sodium-depleted rats and remained unaltered by any of the treatments. The results of the mixed model ANOVA applied to the data on salt and water intake in this experimental set are shown in Table 2 .
3.2. Experiment 2 -effect of the ı-opioid receptor agonist, deltorphin II, on the inhibitory action of naltrindole on salt appetite in sodium-depleted animals
The effect of different doses of Delt-II (2.5, 5, 10 and 20 nmol) on the NTI-induced inhibition of salt intake (20 nmol, n = 12) in sodium-depleted rats is shown in Fig. 2 (Panel A) . As in the previous experiment, at the dose of 20 nmol NTI exerted a significant inhibitory effect on salt intake throughout the entire measurement period compared to sodium-depleted rats receiving LV isotonic saline injections. At the lowest dose, 2.5 nmol (n = 12), Delt-II failed to significantly alter the inhibitory effect of NTI on salt intake. However, at the doses of 5 (n = 13) and 10 nmol (n = 6), the inhibition of salt appetite induced by NTI began to be attenuated at 45 min of the measurement period, and at the dose of 20 nmol (n = 12) this effect was already seen at 30 min of the measurement period. Fig. 2 (Panel  B) shows the effect of LV injections of the ␦-opioid receptor antagonist (NTI 20 nmol) plus the agonist (Delt-II 2.5, 5, 10 and 20 nmol) on water intake in sodium-depleted rats. As expected, water intake was very low in sodium-depleted rats and remained unaltered by any of the treatments. The results of the mixed model ANOVA applied to the data on salt and water intake in this experimental set are shown in Table 2 . The effect of LV injections of Delt-II at the dose of 20 nmol or saline on salt intake in sodium-depleted animals and in normonatremic rats (not submitted to sodium-depletion) is shown in Fig. 3 . In sodium-depleted animals, Delt-II had no effect on the high salt intake when compared to saline-treated, sodium-depleted rats (Panel A). Furthermore, water intake remained unchanged in sodium-depleted rats treated with Delt-II (Panel B). On the other hand, in normonatremic rats, Delt-II (20 nmol) significantly increased salt intake compared to the controls, saline-treated normonatremic rats, after the first 60 min of the measurement period (Panel C). In addition, LV injections of Delt-II (20 nmol) increased the water intake in normonatremic rats after 90 min of the measurement period (Panel D). The results of the mixed model ANOVA applied to the data on salt and water intake in this experimental set are shown in Table 2 .
Experiment 4 -effect of ı-opioid receptor antagonist, naltrindole, on salt and water intake induced by central angiotensinergic stimulation
The effect of LV injections of NTI at the doses of 5 (NTI-5 + AII; n = 10), 10 (NTI-10 + AII; n = 7) and 20 nmol (NTI-20 + AII; n = 8) on cumulative salt intake induced by 10 ng of AII is shown in Fig. 4 , Panel A. As expected, salt intake was significantly higher in the saline + AII group. LV injections of NTI at the doses of 10 and 20 nmol (NTI-10 + AII and NTI-20 + AII) inhibited the salt intake induced by AII after the initial 15 min of the measurement period and lasted until the end of the experiment. The salt intake observed in the NTI-5 + AII group was similar to that of the saline + AII group. Fig. 4 , Panel B, shows the effect of LV injections of NTI at the doses of 5, 10 and 20 nmol on cumulative water intake induced by 10 ng of AII. As expected, water intake was high in the saline + AII group. In the groups treated with LV injections of NTI at any of the doses used, water intake was similar to that of the saline + AII group. The results of the mixed model ANOVA applied to the data on salt and water intake in this experimental set are shown in Table 2 . The letter "a" indicates a statistically significant difference (mixed-model ANOVA followed by Bonferroni's test; p < 0.05) when compared to animals receiving saline; the letter "b" indicates a statistically significant difference when compared to sodium-depleted rats receiving 5 nmol of NTI; the letter "c" indicates a statistically significant difference when compared to sodium-depleted rats receiving 10 nmol of NTI. Each group has been obtained from naïve animals. In the open field test, central blockade of ␦-opioid receptors failed to alter locomotor activity in sodium-depleted rats. Locomotor behavior was similar in sodium-depleted animals receiving LV injections of NTI (20 nmol; n = 11) or saline solution (n = 11). In the dessert test, the hedonic behavior represented by a preference for a palatable solution was confirmed by the higher saccharin (0.1%) intake compared to water intake in the saline-treated control animals. LV injections of NTI (20 nmol; n = 7) failed to alter this hedonic preference.
Experiment 5 -effect of the ı-opioid receptor antagonist on locomotor activity and hedonic behavior in rats
3.6. Experiment 6 -effect of the ı-opioid receptor antagonist on blood pressure in sodium-depleted rats Fig. 6 shows the effects of NTI (20 nmol, n = 8) on blood pressure in rats submitted to sodium depletion using the same experimental protocol used to study salt intake. Baseline blood pressure was 94.4 ± 1.6 mmHg in the group treated with NTI and 100.4 ± 3.7 mmHg in the saline-treated control group. Central administration of NTI failed to modify blood pressure in sodium-depleted animals compared to sodium-depleted controls (saline-treated, n = 5) throughout the entire experimental period. Two-way ANOVA analysis shows that LV injections of NTI induced no significant treatment ( 
Discussion
The aim of the present study was to investigate the role of central ␦-opioid receptors on sodium appetite induced by sodium depletion and by central angiotensinergic stimulation. Preference for hypertonic (1.5%) saline over distilled water was evaluated in both sodium-depleted and sodium-replete rats. The main findings show that blockade of central ␦-opioid receptors inhibits salt intake in sodium-depleted rats, while the pharmacological stimulation of these receptors increases salt intake in sodium-replete animals. Furthermore, the blockade of central ␦-opioid receptors inhibited the salt intake induced by central angiotensinergic stimulation. It was also found that the blockade of ␦-opioid receptors did not change the locomotor activity of the animals, their blood pressure or their preference for saccharin in the dessert test.
Some conditions that induce thirst also trigger sodium appetite [1, 17, 21, 34] . A complex interplay between stimulatory drives such as mineralocorticoid and angiotensin II [23, 62] and negative inputs such as the oxytocinergic [6, 64] and serotonergic inputs [11, 12, 48, 49, 52] is important in the control of salt appetite. In a previous study, our group showed that central kappa-opioid receptor blockade inhibited salt intake in sodium-depleted rats, but failed to alter salt intake in normonatremic animals [55] . These data suggest that k-opioid receptors may be activated during sodium depletion, increasing salt intake. The present study shows that central ␦-opioid receptors may also participate in controlling salt intake. In addition, the present data indicate that the interaction between angiotensinergic and opiadergic systems in the brain is important for the control of sodium appetite in rats.
The opioidergic pathways and opioid receptors are widely distributed throughout the brain [16, 42, 51, 71] . The endorphin family is produced mainly in the arcuate nucleus of the hypothalamus, pituitary and nucleus of the solitary tract. The neuronal system producing enkephalin and dynorphin is more broadly distributed in the brain and it has been reported that in some areas both opioid peptides are present in the same neuron. The endorphin peptides bind mainly to -opioid receptors, while enkephalin binds to ␦-opioid receptors and dynorphin peptides bind to k-opioid receptors [16, 71] .
In the present study, blockade of central ␦-opioid receptors by LV injection of the antagonist naltrindole induced a dosedependent inhibition of salt intake in sodium-depleted rats. This inhibition was reverted by pre-treatment with deltorphin II, a ␦-opioid receptor agonist, at different doses. Both the agonist and the antagonist used in the present study have been shown to be selective for ␦-opioid receptors [20, 38, 57] . Few studies in the literature have evaluated the role of ␦-opioid receptors on salt intake regulation. Intracerebroventricular injection of naltrindole has been shown to have no effect on hypotonic (0.6%) or hypertonic (1.7%) saline intake in the two-bottle (water/saline) preference test, although the dose of naltrindole used in the reported experiments was higher (42 nmol/rat) than the dose used in the present study (5-20 nmol/rat) [7] . Furthermore, in that study, Bodnar's group used 24-h fluid deprivation instead of sodium-depletion to induce salt intake. Sodium-depletion has been shown to be a stronger stimulus for salt appetite than 24-h fluid deprivation [47, 53] . In studies using a sodium-depletion procedure, both systemic and intracerebral injections of naltrindole have been reported to blunt salt appetite [45, 46] . However, in those studies, only one dose of naltrindole was used, whereas in the present study the use of different doses revealed a dose-dependent inhibition of salt appetite in sodium-depleted rats. These data suggest that during sodiumdepletion an increase may occur in endogenous opioid peptides that, by acting on ␦-opioid receptors, regulate salt appetite to correct the sodium imbalance. Indeed, an increase has been reported in the levels of enkephalin mRNA at the shell of the nucleus accumbens in sodium-depleted rats with access to hypertonic saline [45] . Those authors suggested that central enkephalin participates in the reward mechanism controlling salt appetite and the data from the present study corroborate this hypothesis.
One of the mechanisms that may be involved in the regulation of salt appetite in animals submitted to sodium-depletion is the renin-angiotensin system (RAS) [21, 34] . Central injections of angiotensin II promote robust water and sodium intake in normohydrated and normonatremic animals, which can be inhibited by losartan, an AT1 angiotensin receptor antagonist. Inhibition of the angiotensin-converting enzyme (ACE), both in the periphery and in the central nervous system, has been shown to reduce or completely inhibit salt appetite induced by sodium-depletion [34] . The aldosterone and AII produced in the peripheral system and the brain RAS may have a synergic action stimulating salt intake to a greater degree than the action of either hormone alone [24] .
The circumventricular organs such as the subfornical organ (SFO), organum vasculosum of the lamina terminalis (OVLT) and area postrema (AP) are important in sensory sites for humoral signals in blood or interstitial fluid [35, 56, 70] . Indeed, sodium-depletion induced by furosemide injections increases Fos expression in the SFO, OVLT, median preoptic area, central amygdala (CeA), accumbens nucleus (NAc), bed nucleus of stria terminalis (BST), paraventricular, supraoptic, suprachiasmatic and ventromedial hypothalamic nuclei, nucleus of the solitary tract and lateral parabrachial nucleus [18, 30, 54, 59, 65, 67] . Additionally, co-localization of AT1 receptors and Fos protein in the neuronal population of SFO and OVLT has been shown during sodiumdepletion [29] . The increase in neuronal activation induced by sodium-depletion in some brain areas, including the NAc, CeA and BST, is also associated with an increase in the mRNA for enkephalin [30] . The stimulation of these structures during sodiumdepletion may initiate activation of a brain network controlling sodium appetite, and the brain enkephalinergic system may play an important role in this control.
There is some anatomic evidence of an interaction between angiotensinergic and enkephalinergic systems in the brain. In a double immunostaining study using light and electronic microscopic analysis, reciprocal synaptic connections were detected between angiotensin II-containing neurons and enkephalinergic neurons in the area postrema [31] . Furthermore, it has been shown that ACE may participate in the metabolic inactivation of the neuropeptides terminating the enkephalin action [37, 50, 63] . It is interesting to note that in sodium-depleted rats there is some degree of overlap of the brain areas in which there is up-regulation of AT1 receptors mRNA [14, 29] and brain areas in which there is an increase in enkephalinergic mRNA [30] . This provides the necessary anatomical background to support the present findings.
The present study showed that the blockade of ␦-opioid receptors inhibits salt intake in sodium-depleted rats. Since the brain RAS may mediate salt appetite in sodium-depleted rats, we also decided to investigate the effect of a ␦-opioid receptor antagonist on the salt intake directly induced by a central injection of AII. It was found that LV injections of naltrindole inhibit the salt intake induced by central angiotensinergic stimulation in a dose-dependent manner. On the other hand, the water intake induced by angiotensin II remained unchanged by central injections of naltrindole. This finding shows There was no statically significant difference (t-test; p < 0.05) between the group of animals receiving NTI and the saline-treated animals. In the Dessert Test the cumulative saccharin 0.1% and water intake (ml/100 g body weight) was recorded during 2 h after lateral ventricle injections of NTI (20 nmol) or saline. The treatment received by each group and the number of animals used is indicated in the graph. Data are expressed as means ± SEM. There was no statically significant difference (t-test; p < 0.05) when the group of animals receiving NTI was compared to saline-treated group.
that in a two-bottle choice test, blockade of the ␦-opioid receptors specifically inhibits salt preference when the animals are able to choose between water and hypertonic saline, confirming the effect of ␦-opioid receptors on salt preference.
The effect of ␦-opioid receptors on water intake induced by angiotensin II may depend on the experimental protocol used, since central injection of 40 nmol of naltrindole inhibits water intake induced by angiotensin when water is the only fluid available [60] . On the contrary, stimulation of ␦-opioid receptors by deltorphin II increases water intake in normohydrated animals, again, when water is the only fluid available. Furthermore, central injection of deltorphin II increases the water intake induced by a very low dose of angiotensin II (0.02 ng/10 l), but does not change the water intake induced by angiotensin II at a higher dose (2 ng/10 l) [72] .
Pharmacological stimulation of the central ␦-opioid receptors in normonatremic rats, a "salt need-free" condition, induces animals Fig. 6 . Changes in mean blood pressure in sodium-depleted rats after injections of naltrindole (NTI 20 nmol or saline into the lateral ventricle. The injections were given at 0 min and the bottles containing water and saline solution (1.5%) were immediately accessible. Data are presented as means ± SEM. There was no statistically significant difference between the groups (two-way ANOVA; p < 0.05).
to drink a salt solution that is usually aversive. This fact suggests that central ␦-opioid receptors exert a facilitator effect on salt intake behavior. On the other hand, during a "salt hunger" condition (sodium-depletion) an increase may take place in the activation of central ␦-opioid receptors that may change perception of the quality of the salt solution from aversive to palatable, driving animals to consume a large amount of salt until the sodium deficit is replenished. This response reflects sodium appetite and not a hedonic ingestive behavior associated with a tasty salty solution. In a "salt hunger" condition, pharmacological stimulation of ␦-opioid receptors failed to promote a further increase in salt intake. In both "salt need-free" and "salt hunger" conditions, the animals drank a very small volume of water and the blockade or the stimulation of central ␦-opioid receptors had no effect on water intake.
The role of the central opioidergic system in the control of feeding behavior has been shown by several studies, while only a few studies have investigated the participation of central opioid peptides in the regulation of water intake and sodium appetite [8, 9] . Both systemic and intracerebral injections of morphine and the selective opioid receptor agonists increase food intake. In addition, opioid peptides appear to induce a preference for sweet and fatty solutions [8, 9] . Indeed intracerebral administration of morphine and opioid peptide receptor agonists increase fat and sugar intake [9, 26] . Ingestive behavior may be regulated by reward mechanisms involving the hedonic aspects of food and/or fluid intake and the homeostatic nature of the macro and micronutrients [2, 4, 26] . Substantial findings indicate that central opioid system controls feeding behavior through a mechanism which involves the reward and the palatability aspects of food intake [2, 26, 32, 36, 42] . In the present study, the "dessert test", a test used to evaluate the hedonic aspect of ingestive behavior [19, 33] , shows that intake of a palatable saccharin solution is unaffected by LV injections of naltrindole. These data suggest that the changes in salt intake promoted by central ␦-opioid receptors in both normonatremic (salt need-free condition) and sodium-depleted (salt-hunger condition) rats are unrelated to a general change in the palatability mechanisms regulating ingestive behavior.
Central injections of opioid receptor antagonists have been shown to decrease ambulatory and stereotyped activity [43] . These effects could influence ingestive behavior. However, in the present study, no change occurred in locomotor activity in the "open field" test in sodium-depleted rats receiving central injections of naltrindole.
Central opioid peptides may participate in the cardiovascular regulation [8, 66] , and both hypotensive and hypertensive responses have been observed after pharmacological manipulation of central opioid pathways [39] [40] [41] . Changes in blood pressure may affect salt intake; however, a hypertension-induced decrease in salt intake can be excluded as the cause of the inhibitory ingestive behaviors observed in the present study, since intracerebroventricular injections of naltrindole in sodium-depleted rats did not alter blood pressure. Similar results were observed after both systemic [61] and central injections of naltrindole [13, 22] .
The data obtained in the present study confirmed our hypothesis that central ␦-opioid receptors participate in the modulation of salt intake during homeostatic challenges. It is possible that during sodium-depletion, activation of the ␦-opioid receptors regulates salt appetite in order to correct the sodium imbalance, while under normonatremic conditions, ␦-opioid receptors may be necessary to maintain the normal sodium intake. Since in the present study it was observed that blockade of ␦-opioid receptors inhibits salt intake induced by angiotensin II, it is possible to conclude that an interaction between opioidergic and angiotensinergic brain system participates in the control of salt appetite. The decrease in salt intake following central ␦-opioid receptors blockade does not appear to be due to a general inhibition of locomotor activity, changes in palatability or in blood pressure. Given that the circumventricular structures have the ability to detect variations in plasma angiotensin II levels, they may be important as a link between changes in peripheral hydroelectrolyte status and the brain opioidergic system in the control of body fluid homeostasis. However, other studies are need to clarify the brain areas participating in the control of salt appetite modulated by ␦-opioid receptors.
